Orphazyme receives Breakthrough Therapy Designation for arimoclomol in Niemann-Pick Disease Type C (NPC)
November 19, 2019 01:00 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
Financial calendar 2020
November 01, 2019 09:26 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 28/2019Company Registration No. 32266355 Copenhagen, November 1, 2019 –...
Major shareholder announcement
October 02, 2019 10:12 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 27/2019 ...
Orphazyme CMO to speak at FDA-funded rare disease data analytics platform launch event
September 17, 2019 08:22 ET
|
ORPHAZYME A/S
Orphazyme A/SInvestor news No. 04/2019 ...
Orphazyme announces Interim Report First Half 2019
August 28, 2019 01:03 ET
|
ORPHAZYME A/S
Company announcement Orphazyme A/SNo....
Orphazyme strengthens balance sheet with EUR 9 million financing from Kreos Capital
August 27, 2019 15:14 ET
|
ORPHAZYME A/S
Company announcement Orphazyme A/SNo. 25/2019 Company Registration No. 32266355 Loan agreement to...
Orphazyme Interim Report First Half 2019 Presentation
August 21, 2019 06:23 ET
|
ORPHAZYME A/S
Investor news Orphazyme A/SCompany Registration No. 32266355 Copenhagen, Denmark, August...
Major shareholder announcement
August 05, 2019 12:20 ET
|
ORPHAZYME A/S
Company announcement No. 24/2019 Orphazyme...
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
July 29, 2019 14:18 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No....
New phantom share-based incentive program
July 29, 2019 11:19 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 22/2019 ...